Seizures Clinical Trial
Official title:
Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures
NCT number | NCT03233399 |
Other study ID # | 16-01859 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 20, 2017 |
Est. completion date | May 2025 |
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | May 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: (Healthy Controls) - Fluent in English (Patients with PMD or PNES): - Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders. - Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening Exclusion Criteria: - Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI - Chronic or progressive medical condition - Any history of traumatic brain injury or significant head trauma - Currently meets criteria for substance abuse or dependence - History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation - Pregnancy - Metal or devices in the head, including neurostimulators or metal foreign bodies - Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS. - Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.). - Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009 - Current diagnosis of any inflammatory or autoimmune disorder within last 6 months PMD and PNES Patients - Any history of traumatic brain injury or significant head trauma - Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; - Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); - Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months - Metal or devices in the head, including neurostimulators or metal foreign bodies - Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; - Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) =24; - Recurrent visual hallucinations, within the past 6 months; - History of significant uncontrollable movements of the head; - Any clinically significant abnormality on vital signs |
Country | Name | City | State |
---|---|---|---|
United States | New York University School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in signal intensity measured using of tDCS | as a result of altering cerebral perfusion in response to neurophysiologic stimulation | 30 Minutes | |
Primary | Changes in signal intensity measured during EEG recording | as a result of altering cerebral perfusion in response to neurophysiologic stimulation | 3 Hours | |
Primary | Changes in signal intensity measured during MEG | as a result of altering cerebral perfusion in response to neurophysiologic stimulation | 3 Hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02850913 -
Doxycycline for the Treatment of Nodding Syndrome
|
Phase 2 | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Not yet recruiting |
NCT06045676 -
Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital
|
||
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02897856 -
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
|
Phase 4 | |
Completed |
NCT01236001 -
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
|
N/A | |
Completed |
NCT01239212 -
Dosing of Levetiracetam (Keppra) in Neonates
|
Phase 1/Phase 2 | |
Completed |
NCT01702623 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
|
Phase 1 | |
Completed |
NCT01703468 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
|
Phase 1 | |
Recruiting |
NCT02216500 -
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
|
N/A | |
Completed |
NCT00236717 -
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Completed |
NCT05103735 -
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
|
||
Terminated |
NCT03790436 -
Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet
|
N/A | |
Completed |
NCT06451289 -
Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
|
||
Recruiting |
NCT02552511 -
Epidemiology Study on Neonatal Seizure
|
||
Recruiting |
NCT05339126 -
RNS System LGS Feasibility Study
|
Phase 2 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A |